Data / Drug companies / Sam's West Inc
Sam's West Inc: 70 products in the FDA NDC directory, labeler code 68196
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sam's West Inc (labeler code 68196) lists 70 products in the FDA National Drug Code Directory, covering 36 finished drugs by generic name. By type: 70 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 20, 2025.
The request: Watch Sam's West Inc (FDA labeler code 68196): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68196
- Products in commercial distribution
- 70
- Packages
- 83
- Finished drugs by generic name
- 36
- Prescription products
- 0
- Over the counter products
- 70
- Flagged as original packager
- 60 of 60 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- May 24, 1988
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 43 | 61.4% |
| Over the counter monograph drugs | 24 | 34.3% |
| New drug applications (NDA) | 3 | 4.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 70 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 7 | 10% |
| Gum, chewing | 6 | 8.6% |
| Tablet, coated | 6 | 8.6% |
| Lozenge | 6 | 8.6% |
| Tablet, extended release | 6 | 8.6% |
| Tablet, film coated | 5 | 7.1% |
| Solution | 4 | 5.7% |
| Capsule, liquid filled | 4 | 5.7% |
| Liquid | 3 | 4.3% |
| Tablet, delayed release | 3 | 4.3% |
| Spray, metered | 2 | 2.9% |
| Swab | 2 | 2.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Members Mark Arthritis Pain | 68196-611 | Tablet, film coated, extended release | Generic drugs (ANDA) | November 20, 2025 |
| Members mark acetaminophen | 68196-606 | Tablet | Over the counter monograph drugs | November 20, 2025 |
| Acetaminophen | 68196-031 | Tablet, film coated | Over the counter monograph drugs | November 14, 2025 |
| Arthritis Pain | 68196-034 | Tablet, extended release | Generic drugs (ANDA) | August 20, 2025 |
| Maximum Strength Mucus Relief | 68196-033 | Tablet, extended release | Generic drugs (ANDA) | August 20, 2025 |
| Guaifenesin | 68196-960 | Tablet, extended release | Generic drugs (ANDA) | July 31, 2025 |
| Members mark arthritis pain reliever | 68196-523 | Gel | Generic drugs (ANDA) | July 3, 2025 |
| Fluticasone Propionate | 68196-503 | Spray, metered | Generic drugs (ANDA) | July 1, 2025 |
| Members mark mucus relief dm | 68196-812 | Tablet, extended release | Generic drugs (ANDA) | April 3, 2025 |
| Hand Sanitizer Kit | 68196-668 | Kit | Over the counter monograph drugs | March 3, 2025 |
| Members Mark SPF 50 Sunscreen | 68196-603 | Spray | Over the counter monograph drugs | January 8, 2025 |
| Members Mark Childrens Cetirizine | 68196-475 | Solution | Generic drugs (ANDA) | September 23, 2024 |
| Foaming Antibacterial | 68196-667 | Solution | Over the counter monograph drugs | September 16, 2024 |
| Members Mark Triple Antibiotic | 68196-400 | Ointment | Over the counter monograph drugs | September 5, 2024 |
| Members Mark Lansoprazole | 68196-279 | Capsule, delayed release | Generic drugs (ANDA) | July 15, 2024 |
| Alcohol | 68196-602 | Liquid | Over the counter monograph drugs | July 1, 2024 |
| Low Dose Aspirin | 68196-481 | Tablet, coated | Over the counter monograph drugs | July 1, 2024 |
| Allergy Relief | 68196-160 | Tablet | Over the counter monograph drugs | July 1, 2024 |
| Ibuprofen | 68196-601 | Tablet, coated | Generic drugs (ANDA) | June 15, 2024 |
| Members mark allergy relief | 68196-711 | Tablet | Generic drugs (ANDA) | March 11, 2024 |
| Members Mark Allergy Relief | 68196-413 | Tablet, film coated | Generic drugs (ANDA) | March 8, 2024 |
| Acetaminophen | 68196-177 | Tablet | Over the counter monograph drugs | February 13, 2024 |
| Members mark omeprazole | 68196-700 | Tablet, delayed release | New drug applications (NDA) | February 7, 2024 |
| Guaifenesin | 68196-405 | Tablet | Generic drugs (ANDA) | October 6, 2023 |
| Members Mark Mucus Relief DM | 68196-999 | Tablet, extended release | Generic drugs (ANDA) | August 15, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.